# Pola-ZR2P in Previously Untreated DLBCL

> **NCT06664411** · PHASE2 · RECRUITING · sponsor: **Navy General Hospital, Beijing** · enrollment: 80 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction Therapy

## Key facts

- **NCT ID:** NCT06664411
- **Lead sponsor:** Navy General Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-24
- **Primary completion:** 2029-12
- **Final completion:** 2030-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06664411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06664411, "Pola-ZR2P in Previously Untreated DLBCL". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06664411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*